Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Budesonide for Checkpoint Inhibitor Pneumonitis
NCT06860542Phase 2Recruiting
- Sponsor
- American Health Staffing Group
- Start
- Feb 2026
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of budesonide in Checkpoint inhibitor pneumonitis (CIP) (2 arms), sponsored by American Health Staffing Group. Primary endpoint: Rate of Refractory or Recurrent Checkpoint Inhibitor Pneumonitis at 1 year. Started Feb 2026; status: recruiting.
02
Drugs
budesonide
03
Conditions
Checkpoint inhibitor pneumonitis (CIP)
Beyond the preview
Go deeper on NCT06860542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06860542.